Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating oral difelikefalin (CR845) for moderate to severe pruritus in subjects with nontalgia paresthetica has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Notalgia Paresthetica
• Pruritus

Drugs mentioned

• Difelikefalin (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Pruritus, Notalgia Paresthetica | Phase 2 | Status: COMPLETED